Alexei V. Demchenko, PhD and Michael R. Nichols, PhD, University of Missouri - St. Louis

Alexei V. Demchenko, PhD
Nichols, PhD
Michael R. Nichols, PhD

The Demchenko and Nichols laboratories have discovered a new class of compounds that can serve as a Lipid A-like LPS antagonist and has downstream potential as a therapeutic agent for microbial sepsis. The compounds may also have effectiveness in other inflammatory disease scenarios that trigger a similar pathway.

The Investigator's Annexe Part of The Investigator's Annexe program.



  1. Kaeothip S, Paranjape G, Terrill SE, Bongat AFG, Udan MLD, Kamkhachorn T, Johnson HL, Nichols MR, Demchenko AV. Development of LPS antagonistic therapeutics: synthesis and evaluation of glucopyranoside-spacer-amino acid motifs. RSC Advances, 2011, 1, 83-92.